Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as reduction in liver fibrosis at 80 mg/kg, po administered daily for 4 weeks by picrosirius red staining method
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Invivo activation of FXR in SCDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as improved glucose tolerance measured up to 120 mins by glucose tolerance test
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of SHP gene expression in liver at 80 mg/kg, po administered daily for 4 weeks
Assay data:1 Active, 2 Tested
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of OST-alpha gene expression at 80 mg/kg, po administered daily for 4 weeks
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of IBABP gene expression at 80 mg/kg, po administered daily for 4 weeks
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of SHP gene expression at 80 mg/kg, po administered daily for 4 weeks
Invivo activation of FXR in CDAHFD-induced nonalcoholic steatohepatitis C57BL/6J mouse model assessed as induction of FGF15 gene expression at 80 mg/kg, po administered daily for 4 weeks
Agonist activity at mouse LBD fused FXR in HEK293 cells incubated for 30 min by envision plate reader method
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Agonist activity at LBD-fused mouse FXR in HEK293 cells incubated for 30 min by envision plate reader method relative to GW2064
Assay data:2 Tested
SummaryPubMed CitationRelated BioAssays by Target
Invivo antagonist activity against FXR in mouse assessed as reduction in Tgr5 expression in small intestine organoids
Assay data:1 Active, 1 Tested
Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced FXR mRNA expression in hepatic signaling at 10 mg/kg, po incubated for 2 to 48 hrs
Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced Fgf15 mRNA expression in ileum at 10 mg/kg, po incubated for 2 to 48 hrs
Invivo antagonist activity against FXR in microbeta depleted mouse assessed as reduction in taurocholic acid induced Shp mRNA expression in ileum at 10 mg/kg, po incubated for 2 to 48 hrs
Invivo antagonist activity against FXR in mouse assessed as reduction in Shp level in presence of GW4064
Invivo antagonist activity against FXR in mouse assessed as reduction in Fgf15 level in presence of GW4064
Invivo antagonist activity against FXR in mouse assessed as reduction in Fxr level in presence of GW4064
Invivo antagonist activity against FXR in mouse assessed as reduction in Fgf15 level in presence of CDCA
Invivo antagonist activity against FXR in mouse assessed as reduction in Fxr level in presence of CDCA
Invivo antagonist activity against FXR in mouse assessed as reduction in Fgf15 level at 50 uM
Assay data:1 Tested
Invivo antagonist activity against FXR in mouse assessed as reduction in Fxr level at 50 uM
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on